Health Care & Life Sciences » Pharmaceuticals | Catalyst Biosciences Inc.

Catalyst Biosciences Inc. | Ownership

Companies that own Catalyst Biosciences Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Acuta Capital Partners LLC
830,000
6.95%
-324,722
1.58%
06/30/2018
Nexthera Capital LP
786,865
6.59%
248,241
1.92%
06/30/2018
BlackRock Fund Advisors
715,351
5.99%
529,203
0%
06/30/2018
Point72 Asset Management LP
600,350
5.03%
600,350
0.03%
06/30/2018
Renaissance Technologies LLC
586,573
4.91%
30,200
0.01%
06/30/2018
Marshall Wace LLP
550,352
4.61%
550,352
0.08%
06/30/2018
The Vanguard Group, Inc.
543,492
4.55%
175,331
0%
06/30/2018
Sio Capital Management LLC
471,448
3.95%
-678,541
2.84%
06/30/2018
Ghost Tree Capital LLC
355,000
2.97%
-95,000
1.06%
06/30/2018
Eventide Asset Management LLC
246,000
2.06%
246,000
0.1%
06/30/2018

About Catalyst Biosciences

View Profile
Address
611 Gateway Boulevard
South San Francisco California 94080
United States
Employees -
Website http://www.catalystbiosciences.com
Updated 07/08/2019
Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel medicines to address hemophilia condition. Its product pipeline includes FVIIa for the treatment of hemophilia A or B with inhibitors, FIX for hemophilia B treatment, and FXa, which is a universal pro-coagulant. It also develops Anti-C3 CB 2782 for dry age-related macular degeneration.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.